Imide Condensation as a Strategy for the Synthesis of Core-diversified G-quadruplex Ligands with Anti-cancer and Anti-parasitic Activity by Street, Steve et al.
                          Street, S., Peñalver, P., O'Hagan, M., Hollingworth, G., Morales, J. C.,
& Galan, M. C. (2021). Imide Condensation as a Strategy for the
Synthesis of Core-diversified G-quadruplex Ligands with Anti-cancer
and Anti-parasitic Activity. Chemistry - A European Journal, 27(28),
7712-7721. https://doi.org/10.1002/chem.202100040
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1002/chem.202100040
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Wiley at
https://doi.org/10.1002/chem.202100040 .Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Imide Condensation as a Strategy for the Synthesis of Core-
Diversified G-Quadruplex Ligands with Anticancer and
Antiparasitic Activity**
Steven T. G. Street,[a, b] Pablo Peñalver,[c] Michael P. O’Hagan,[a] Gregory J. Hollingworth,[d]
Juan C. Morales,*[c] and M. Carmen Galan*[a]
Abstract: A facile imide coupling strategy for the one-step
preparation of G-quadruplex ligands with varied core chem-
istries is described. The G-quadruplex stabilization of a library
of nine compounds was examined using FRET melting experi-
ments, and CD, UV-Vis, fluorescence and NMR titrations,
identifying several compounds that were capable of stabiliz-
ing G-quadruplex DNA with interesting selectivity profiles.
The best G4 ligand was identified as compound 3, which was
based on a perylene scaffold and exhibited 40-fold selectivity
for a telomeric G-quadruplex over duplex DNA. Surprisingly, a
tetra-substituted flexible core, compound 11, also exhibited
selective stabilization of G4 DNA over duplex DNA. The
anticancer and antiparasitic activity of the library was also
examined, with the lead compound 3 exhibiting nanomolar
inhibition of Trypanosoma brucei with 78-fold selectivity over
MRC5 cells. The cellular localization of this compound was
also studied via fluorescence microscopy. We found that
uptake was time dependant, with localization outside the
nucleus and kinetoplast that could be due to strong
fluorescence quenching in the presence of small amounts of
DNA.
Introduction
G-quadruplexes (G4s) are a class of secondary nucleic acid
structures formed from guanine-rich sequences. These motifs
have garnered significant attention in recent years, as a wide
variety of potential applications and functions continue to
emerge.[1] Since the discovery of the first G4 DNA stabilizing
ligand by Neidle and Hurley et. al. in 1997[2] the field of G4
interactive compounds has experienced exponential growth.[3]
Advances in our understanding of G4 biology have driven new
discoveries of the potential biomedical applications of G4
ligands in the therapeutic targeting of numerous diseases.[4]
Whilst much attention has focused on the use of this strategy
for the treatment of cancer,[5] recently their potential to be
deployed as antiparasitic agents has come to light.[6] The
stabilization of key G4-forming sequences in gene promoters is
proposed to prevent the binding of transcription factors and
lead to downstream gene silencing and toxic effects. Induction
of the G4 motif at chromosome telomeres is also demonstrated
to induce toxicity via inhibition of telomerase, a known
anticancer target.
Whilst numerous small molecules have been reported to
interact with G4 DNA for use as therapeutics,[7] only a handful
have been investigated clinically[8] due to challenging synthe-
ses, poor bioavailability, and poor target specificity.[7c] Whilst
significant progress has been made, it is clear that efficient
methods to rapidly generate diverse libraries of potential G4
ligands are needed to provide us with a better understanding
of the parameters that govern G4 stabilization, destabilization,
and target selectivity, which are key requirements for the
development of clinically viable G4 interactive small molecules.
Recent efforts in our groups have been focused on the
development of a series of G4 targeting compounds derived
from the naphthalene diimide (NDI) scaffold.[9] We found that
di-substituted diimides, particularly NDI-glycoconjugates, dis-
played interesting selectivity profiles towards G4 structures with
lead compounds 1 and 2 (Figure 1, A) stabilizing particular G4
topologies with good discrimination. Moreover, compound 1
exhibited submicromolar activity against cancerous cell lines.
Though NDI cores have been extensively studied as the basis of
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G4-targeting molecules,[10] to date there has been no systematic
exploration of different diimide scaffolds to probe the role of
the ligand core in driving G4 binding, and to identify new core-
forming motifs. In this work, we utilize the simplicity of imide
coupling chemistry to develop, in one step, a library of
functional, amphiphilic small molecules with a variety of differ-
ent cores from commercially available materials. The work
herein probes the role of core flexibility, structure, and
electronics in facilitating G4 binding, and examines whether
ligand G4 stabilisation is correlated with antiparasitic or
anticancer activity in vitro.
Figure 1. Compounds studied in this work, utilizing imide-based coupling of a variety of commercially available building blocks. (A) Lead compounds 1 and 2
from previous work,[9] and control G4 ligand PIPER.[12] (B) New compounds 3–11 studied in this work, probing the role of core flexibility, aromaticity, and
electronics on G-quadruplex binding.
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Results and Discussion
Previous work on G4 ligands[11] indicates that 1-(3-amino-
propyl)-4-methylpiperazine is an effective side chain that is
capable of conferring G4 recognition properties and aqueous
solubility to aromatic cores. We thus rationalized that coupling
this readily-available motif with a range of commercially
available anhydride cores would yield a library of interesting
amphiphiles in one step, allowing for fast diversification and
generation of novel G4 binding motifs (Scheme 1). As a proof of
concept, we started by examining seven different commercially
available dianhydrides, which together probe a variety of
features important for G4 binding, such as the flexibility of the
central scaffold, the role of electronic and steric effects,
conformational freedom, and the number and presentation of
the aromatic rings. Nine new compounds were produced in
total (Figure 1, B). The imide coupling reaction is compatible
with a wide range of solvents; good results were obtained in
toluene for many of the dianhydrides examined, whilst
imidazole was used as the solvent for the synthesis of perylene
diimide (PDI) 3, due to the limited solubility of perylene-
3,4,9,10-tetracarboxylic dianhydride. Purification of the resulting
compounds by reverse-phase flash chromatography (water+
0.1% trifluoroacetate (TFA)/MeCN, 9 :1 to 5 :95) was sufficient to
protonate the methylpiperazine rings, yielding the final com-
pounds as water soluble TFA salts.
Compounds 3–9 were prepared in yields ranging from 16–
79% as di-substituted bisimides, while tetra-substituted com-
pounds 10 and 11 were obtained serendipitously in the
presence of an excess of amine in 40 and 75% yield,
respectively (Scheme 1). PIPER was also synthesized according
to the reported procedure,[12] and used as a positive control.
Curiously, the dianhydrides used in 10 and 11 were the only
cores where tetra-substitution was observed. Further investiga-
tion of LC-MS results from the isolated fractions of 11 revealed
the presence of tri-substituted species containing an imide and
two amides as a minor product (MH2
2+ =479). There was no
evidence of tri-substituted species containing three amides and
one carboxylic acid (expected MH2
2+ =488). Analysis of LC-MS
data from the isolated fractions of 10 revealed the presence of
multiple species with different core substitution patterns,
amongst them the tri-substituted species with an imide and
two amides (MH2
2+ =380) as well as the di-substituted bisimide,
and the bis(amide/carboxylic acid). Again, no evidence of the
tri-substituted species containing three amides and one carbox-
ylic acid was found (expected MH2
2+ =389). The presence of
multiple species with a lower degree of substitution is in
accordance with the lower yield obtained for compound 10
(40%) compared to 11 (75%) and indicates that this reaction
proceeded to a lesser degree of completion. These results
suggest that tetra-substitution of 10 and 11 goes through the
bisimide intermediate, which is presumably ring-opened by
further nucleophilic addition. The variation in isolated yields can
be explained by several factors. Comparing the synthesis of PDI
3 (yield 39%) with PIPER (yield 77%), it is clear that water is a
better solvent than molten imidazole for the synthesis of
amphiphilic PDIs. The low yields for compounds 7 (yield 33%)
and 9 (yield 16%) can be explained by competition between
the desired di-substituted product and undesired tri- and tetra-
substituted side products, which are removed during purifica-
tion. Also in the case of 9, it would appear that DMSO/NEt3 are
not favourable reaction conditions for imide condensation. The
remaining variation in yield likely results from interplay
between the sterics and electronics of the cores, though no
obvious trends stand out.
With the library in hand, we began our investigation into G4
stabilization by conducting a Förster resonance energy transfer
(FRET) melting assay to assess DNA stabilization using the
procedure outlined by De Cian et. al.[13] Briefly, compounds 1
and 3–11 were tested against four model G4-forming oligonu-
cleotides and a hairpin duplex sequence to assess G4:Duplex
selectivity as well as G4:G4 selectivity. The sequences examined
(at 200 nM) were the human telomeric G4 in potassium buffer
(F21T-K+, mixed parallel/hybrid G4)[14] and sodium buffer (F21T-
Na+, antiparallel G4),[15] the c-Myc promoter G-quadruplex
(FmycT-K+, parallel G4),[16] a polymorphic G4 found in T. brucei
(FEBR1T-K+, a mixed G4 topology),[6b] and a hairpin duplex DNA
sequence (F10T-K+). Together, these sequences represent
targets for therapeutic intervention to treat parasitic
infections,[6b] or cancer.[1b] The topology of each sequence was
confirmed independently via circular dichroism (CD, Figure S1).
Initially, all compounds were tested at 10 μM concentration
(Table S1 and Figure S2), with active ligands also being tested
at 5 μM (Table 1) and 1 μM (Table S2). Results revealed that only
compounds 3, 9 and 11 were capable of stabilizing G4
structures (Table 1 and Figure S2), although compound 9 only
exhibited stabilization at the highest concentration of 10 μM.
Scheme 1. The one-step synthesis of the nine compounds studied in this
work. Conditions were: toluene, 145 °C for 4–8 and 10–11; imidazole, 145 °C
for 3 and DMSO, NEt3, 80 °C for 9. For experimental details, see Supporting
Information.
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Whilst PDI based ligands PIPER and 3 exhibited large shifts in
ΔTm for all G4 structures and minimal shifts in ΔTm for duplex
structures (Figure S3–4), spectral overlap between the PDI core
and the FAM/TAMRA FRET pair in the 450–650 nm region
prevents definitive conclusions about DNA stabilization from
FRET melting experiments. Despite this, a significant difference
was observed between the apparent ΔTm for G4 sequences and
the duplex sequence. Compounds 9 and 11 also displayed
some mild stabilization of G4 DNA, with minimal stabilization of
the F10T duplex (Figure S5-6). Tetra-substituted ligand 11 had
superior stabilization over di-substituted 9, in agreement with
the number of basic residues being a primary driver for G4
stabilization.[9,10d,17] Lead compound 1 also exhibited modest
stabilization of the parasitic Febr1T-K+ G4 (Figure S7). The lack
of G4 stabilization of compounds 4–8 and 10 can likely be
attributed to the increased conformational freedom and
reduced hydrophobic aromatic surfaces present in many of the
structures. Thus, our data suggests that aromatic π-π stacking
interactions and structural rigidity of the core motif are key
driving forces for G-quadruplex stabilization, and should be
considered as important factors alongside the number and
location of basic residues when designing optimum G-quad-
ruplex interactive compounds. More rigid cores not only
provide hydrophobic and π-π stacking interactions with
terminal G-tetrads, but also facilitate the correct orientation of
side chains into the G4 grooves, leading to a lower entropic
penalty for adopting the optimal conformation compared to
more flexible cores. Interestingly, our approach also reveals that
flexible cores with enough positively charged groups, such as in
compound 11, can show G4 binding ability with a certain
selectivity over duplex DNA.
To further probe the G4 and duplex DNA stabilization
potential of ligands 1, 3, 9, and 11, Circular Dichroism (CD)
studies were conducted on four different oligonucleotide
structures (Figure 2 and S8–9). These were: telo23-K+ (which
forms a hybrid G4),[14] telo22-Na+ (which forms an antiparallel
G4),[15] EBR1-K+ (which forms a mixed G4)[6b] and ds26-K+ (which
forms a self-complementary duplex). Together, these sequences
cover a range of DNA topologies with therapeutic potential.
The EBR1-K+ G4 is specific to T. brucei, whilst the telomeric G4s
(telo23-K+ and telo22-Na+) are common to both human and T.
brucei genomes. Oligonucleotide concentrations were 5 μM in
all cases, whilst ligand concentration was varied from 1 to 10
equivalents. Results from the titration of 1 with the EBR1-K+ G4
and ds26-K+ duplex revealed perturbation of both structures
upon binding (Figure S8). This is similar to the G4 disruption
previously observed for the perturbation of 1 with telo23-K+
and telo22-Na+G4’s.[9] These results are also in accordance with
previous observations of the G4:duplex selectivity of 1, where a
significant reduction in G4 stabilization was observed via FRET
melting experiments when competitor duplex DNA was
present.[9] Titration of 3 with each oligonucleotide revealed
Table 1. DNA stabilization of PIPER and 1, 3, 9 and 11 assessed via FRET
Melting Assay at 5 μM ligand and 200 nM DNA concentration. (ΔTm
reported to 1 °C using ΔTmax, error is reported as σ). Buffers composition
was 10 mM KCl, 90 mM LiCl and 10 mM Li cacodylate for F21T-K+, Febr1T-
K+ and F10T-K+; 1 mM KCl, 99 mM LiCl and 10 mM Li cacodylate for
FmycT-K+; and 100 mM NaCl and 10 mM Li cacodylate for F21T-Na+. Data
for 1 against non-parasitic G4 s has been previously reported and is
reproduced with permission.[9]
Compound F21T-K+ F21T-Na+ FMycT-K+ Febr1T-K+ F10T-K+
PIPER[a] 37�2 17�2 21�2 33�1 1�1
1 14�2 -2�1 7�2 9�1 1�1
3[a] 34�1 35�4 37�2 33�1 6�2
9   1�1   4�1   1�2   4�1 0�1
11 7�2 1�1 5�1 6�1 0�1
[a] Spectral overlap between the ligand and the FAM/TAMRA FRET pair
may interfere with these results. Additionally, the oligonucleotide did not
completely unfold under these conditions. These results are therefore not
reliable indications of DNA Stabilization.
Figure 2. CD titrations of compounds 3 and 11 with telo23-K+, telo22-Na+, EBR1-K+ (G-quadruplex) and ds26-K+ (duplex) DNA structures, probing the effects
of the compounds on DNA topology. (A–D) Effects of 3 on the (A) telo23-K+, (B) telo22-Na+, and (C) EBR1-K+ G-quadruplex structures, and (D) the ds26-K+
duplex. (E–H) Effects of 11 on the (E) telo23-K+, (F) telo22-Na+, and (G) EBR1-K+ G-quadruplex structures, and (H) the ds26-K+ duplex. Red arrows denote
changes in molar ellipticity observed, whilst the red underlined region denotes induced CD from 3. Oligonucleotide concentration was 5 μM, with ligand
concentration varied up to 10 equivalents (50 μM). For full details, see Supporting Information.
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perturbations in the observed CD signal for every structure, and
were more significant with the EBR1-K+ G4 and ds26-K+ duplex.
It is interesting to note the presence of an induced CD band at
400–600 nm that is either due to induced CD from interaction
with the oligonucleotide, or from the ligand itself, as PDIs are
known to aggregate into helical structures with CD bands in
this region.[18] However a control titration of the ligand into
buffer in the absence of DNA revealed no CD signal (data not
shown). The induced CD signal can therefore be attributed to
the binding of ligand 3 to the chiral DNA structures. Di-
substituted ligand 9 exhibited no effect on any DNA structure
examined via CD (Figure S9). In contrast, tetra-substituted
ligand 11 modified the CD signal of the telo22-Na+ G4 and the
EBR1-K+ G4 upon binding, showing no change when binding
to the telo23-K+ G4 or the ds26-K+ duplex structure.
To obtain quantitative information on the binding of NDI 1
and PDI 3 to the previously assessed G4 and duplex DNA
structures, ultraviolet-visible absorbance spectroscopy (UV-Vis)
titrations were conducted (Figure 3 and S10). In all cases the
ligand concentration was kept constant at 10 μM, whilst
oligonucleotide was titrated in up to a final concentration of
30 μM. The observed binding isotherms were fitted to an
independent/equivalent sites binding model, and binding
constants (Ka) were determined. Results from the titration of
telo23-K+, telo22-Na+, EBR1-K+ and ds26-K+ oligonucleotides
into a solution of NDI 1 (Figure 3 and S10) revealed hypochro-
micity, and a red-shift in the absorbance of the ligand, which is
indicative of end-stacking interactions with the G4 sequences.
The titration with telo23-K+ and telo22-Na+ yielded a Ka of 6×
106 and 6×104, respectively. The Ka determined for the binding
of 1 to the telo23-K+ G4 via UV-Vis is in agreement with the Ka
determined previously via isothermal titration calorimetry
(ITC).[9] The 100-fold selectivity observed for the hybrid form of
the telomeric G4 over the anti-parallel form is also in agreement
with previous observations from FRET melting assays,[9] provid-
ing quantitative information on the unique interactions 1 has
with different topologies of the telomeric G4. Examples of G4
ligands with this level of discrimination between different G4
topologies are comparatively rare, and further examination of
this apparent selectivity might yield useful insights into the
future developments of compounds with interesting G4:G4
discrimination. Compound 1 also exhibited significant binding
to the EBR1-K+ G4 and ds26-K+ duplex (Ka=2×10
6 and 1×106,
respectively). These results confirm the significant binding to
duplex DNA observed for compound 1, which is similar to its
affinity for the EBR1-K+ G4, and indicate that it is not as
selective for G4 structures over duplex structures as FRET
measurements suggest. Attempts to fit the observed binding
isotherms to a 1 :1 binding model were unsuccessful, resulting
in poor fitted curves, whilst a 2 :1 model described the data
more convincingly. This is in agreement with the 2 :1
stoichiometry observed via ITC for the telo23-K+ G4 observed
previously for compound 1,[9] and is also in agreement with
potential end-stacking of the ligand on terminal G-tetrads.
Results from the titration of the various oligonucleotides into a
solution of PDI 3 revealed a similar affinity for the telo23-K+ G4
(Ka=2×10
6), but a much better selectivity profile, with 40-fold
selectivity over the ds26-K+ duplex (Ka=5×10
4) and ~7-fold
selectivity over the EBR1-K+ G4 (Ka=3×10
5) versus 6-fold and
3-fold, respectively, for 1.
Unlike NDI 1, PDI 3 displayed appreciable binding to the
telo22-Na+ G4 (Ka=8×10
5), indicating that the specific selectiv-
ity observed for 1 is not applicable to the larger PDI core of 3
(Figure 3 and S10). Like compound 1, 3 was also best described
by a 2 :1 binding model over a 1 :1 model. The initial
absorbance profile of PDI 3 was consistent with literature
reports of aggregated perylene bisimide dyes, and inconsistent
with the absorbance spectra of monomeric PDIs, indicating that
3 exists in an aggregated form under these conditions.[18,19]
Additionally, we observed the presence of a shoulder at
550 nm, which is associated with the presence of face-to-face
π-π stacks of the PDI core (H-aggregates)[18,19a] and comparable
to the charge-transfer exciton band reported for the perylene
analogue perylenetetracarboxylic dianhydride,[20] indicating that
Figure 3. UV/Vis binding isotherms and binding constants (Ka) for the
association between compounds 1 (A) and 3 (B) with telo23-K+, telo22-Na+,
EBR1-K+, and ds26-K+ DNA structures, following the change in ligand
absorbance at 384 nm for 1 (A) or 550 nm for 3 (B). (C) Binding constants
determined for the association of 1 and 3 with each of the DNA structures
examined, fitted using an independent/equivalent sites binding model, with
2 :1 ligand:DNA stoichiometry. Ligand concentration was 10 μM, with
oligonucleotide concentration varied up to 30 μM. For full details, see
Supporting Information.
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the PDI cores are in close proximity to each other. The
aggregation of 3 under aqueous conditions was further
reinforced by comparing the NMR spectra of 3 in water with
that in CDCl3 (Figure S11). In CDCl3, the spectrum is well
resolved, with observable fine structure. In water, significant
line-broadening is observed, with a complete loss in fine
structure which is in accordance with aggregated species.[21]
Upon addition of DNA, a hyperchromic shift in absorbance is
observed, with the absorbance profile of 3 exhibiting well-
resolved vibrionic structure, resembling that of monomeric
PDIs.[18,19,22] This data demonstrates that PDI 3 undergoes
disaggregation in the presence of the DNA sequences exam-
ined here, leading to monomeric PDIs that are bound to G4 or
duplex DNA. These results imply that the Ka for the binding of 3
to the G4 and duplex sequences examined here must be higher
than the Ka for the self-association of 3 which leads to
aggregation. Thus, the presence of the G4/duplex sequences
examined is sufficient to induce the disaggregation of PDI 3.
This observation is in agreement with previous work by Kern et.
al.[19a,22] who showed that the binding of PDIs to G4 and duplex
DNA is mediated through ligand disaggregation. Unfortunately,
the absorbance of compounds 9 and 11 overlapped with the
absorbance from the oligonucleotide (λabs <300 nm), prevent-
ing analysis via UV-Vis titration.
To further investigate the effects of DNA binding on PDI 3,
fluorescence titrations were conducted on the previously
assessed G4 and duplex DNA structures (telo23-K+, telo22-Na+,
EBR1-K+ and ds26-K+). The concentration of 3 was kept
constant at 1 μM, and the concentration of oligonucleotide was
varied up to 1 μM. The results (Figure 4 and S12) reveal that 3
undergoes significant fluorescence quenching in the presence
of DNA. Interestingly, a high level of fluorescence quenching
was observed at very low levels of DNA, with a ligand:DNA ratio
of 5 : 1 for ds26-K+ and between 7 :1 to 10 :1 for G4 DNA. This
phenomenon has been previously observed for the binding of
PDI ligands to G4 and duplex DNA.[19a] The stoichiometry of
>5 :1 is in stark contrast to the stoichiometry observed via UV-
Vis and implies that phenomena other than specific binding to
DNA may be responsible for the observed fluorescence
quenching. Considering that PDI 3 has been shown to undergo
aggregation in aqueous conditions, we hypothesize that the
reduction in fluorescence is likely due to the disaggregation
phenomena, which may result in increased fluorescence
quenching. The sharpest fluorescence quenching was observed
for telo23-K+, which is in accordance with UV-Vis data that
suggested 3 has the strongest interaction with this structure.
The lowest fluorescence quenching was observed for ds26-K+,
which is also in agreement with UV-Vis data that suggested 3
has the weakest interaction with duplex DNA. Whilst the EBR1-
K+ G4 also displayed a similar fluorescence quenching profile to
telo23-K+, telo22-Na+ induced a lower level of fluorescence
quenching, similar to that of ds26-K+, which is in contrast to the
binding observed via UV-Vis. Overall, fluorescence titrations
revealed that 3 undergoes significant fluorescence quenching
in the presence of G4 DNA, and a lower degree of fluorescence
quenching in the presence of duplex DNA.
To further assess how compounds 1, 3, 9 and 11 interacted
with G4 DNA, NMR titrations were conducted with the telo22-
Na+ G4, as it forms a single, well-defined topology – the
antiparallel basket (Figure 5 and S13). The oligonucleotide
concentration was kept constant at 185 μM, and 0.25, 0.5, 1, or
2 equivalents of ligand were added. The spectrum for the
oligonucleotide in aqueous buffer was indicative of an antipar-
allel basket (Figure 5A) and addition of DMSO as a control
ligand barely changed the NMR signals. Results for the titration
with 1 revealed significant perturbations of all protons in the
imino and aromatic regions and a minor shift for the G9 imino
proton (Figure 5B). This could be consistent with 1 interacting
with the terminal G-tetrads and a stoichiometry of 2 : 1, if, at the
same time, it is inducing significant topological changes to the
quadruplex upon binding that also affects the internal G4
tetrad. In fact, end-stacking would mean significantly affecting
the lateral and diagonal loops configuration since they may
prevent the NDI core motif from efficiently stacking on the
terminal G tetrad. These results are also consistent with
previous molecular docking studies of 1, which also suggested
an end-stacking binding mode.[9] Furthermore, this scenario
may also provide a plausible explanation for the low binding
constant observed for 1 against the telo22-Na+ G4 due to this
potential induced-fit binding mechanism.
In contrast, PDI 3 had no discernible change on the
chemical shift of the telo22-Na+ G4 despite the interaction
being observable via CD, UV-Vis, and fluorescence (Figure S13B).
This effect has been observed for other G4 ligands such as
Neidle’s diphenyl triazole ligands when binding to telo22-Na+
or HIVPRO1 G4’s and has been attributed to unspecific
binding.[23] In case of compound 3 which shows concentration-
dependant aggregation, the high concentrations used in the
NMR titration could alter the equilibrium between the PDI
aggregates and binding to G4 DNA, favouring PDI aggregation
and a weak association with the telo22-Na+ G4. Similarly, di-
substituted 9 also exhibited minimal effects on the telo22-Na+
G4 (Figure S13C), which is in accordance with the minimal
topological change upon binding revealed by the CD titrations,
and also points to potential unspecific binding. In contrast,
tetra-substituted 11 exhibited small specific perturbations of
imino protons G4 and G14 as well as aromatic protons both in
Figure 4. Binding isotherms for association of 3 (1 μM) with up to 1 μM of
(A) telo23-K+, (B) telo22-Na+, and (C) EBR1-K+ G-quadruplex and (D) ds26-K+
DNA, following the change in fluorescence of 3 at 550 nm. For full details,
see the Supporting Information.
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the tetrads (G3, G8 and G20) and in the loops (T5, T6, T11 and
T18, Figure 5C). This indicates binding interactions predom-
inantly located at the upper tetrad and on one of the grooves,
with a clear different mode to that observed for compounds 1,
3 and 9, possibly due to its tetra-substitution with four positive
charged groups in an octopus-like arrangement.
To investigate the potential anticancer and antiparasitic
activity of compounds 1 and 3–11, cytotoxicity assays were
conducted on MRC5 non-tumoral cells and on HeLa cervical
carcinoma cells, as well as T. brucei and L. major parasites.
Doxorubicin, suramin and miltefosine were used as control
compounds.[6b,9] After incubation with varied concentrations of
the compounds for 72 h, cell viability was measured using
either an alamarBlue™ assay (for MRC5, HeLa and T. brucei) or
MTT assay (for L. major). Absolute EC50 values and selectivity
indexes were then calculated from dose-response curves
(Table 2 and S14). The results revealed that G4 interactive
compounds 1, 3, 9, and 11 all inhibited cell viability, with the
highest selectivity index for HeLa cells over MRC5 cells obtained
by compound 1 at 10-fold. The most active compounds against
parasites were 1, 3 and 11, which also exhibited the highest G4
stabilization. All three were particularly effective against T.
brucei, with 3 exhibiting the best EC50 value in the nanomolar
range. Compounds 3 and 11 showed the highest selectivity for
T. brucei over MRC5, with 3 displaying a 78-fold selectivity. This
represents a large potential therapeutic window, since consid-
erably lower toxicity is observed towards non-tumoral MRC5
cells (EC50=2 μM). The efficacy and selectivity of 1, 3 and 11 for
T. brucei over MRC5 was higher than for other typical G4
interactive compounds such as Pyridostatin and BRACO-19 (EC50
values of 5.5 and 7.8 μM, and selectivity index (SI) of 0.7 and
1.5, respectively).[6b] In the case of the activity towards L. major,
only compounds 1 and 11 displayed relevant toxicity (EC50
values of 0.47 and 18 μM, respectively). Whilst no correlation
between G4 stabilization and anticancer activity was observed
for these compounds, cytotoxicity towards T. brucei was
correlated with G4 stabilization, with 1, 3 and 11 all exhibiting
antiparasitic activity. Certainly, other mechanisms of action
must also be considered and will be studied in the future.
The inherent fluorescence of PDI 3 enabled us to track its
localization in both cells and parasites. Preliminary absorbance
and fluorescence experiments indicated that 3 exists in H-
aggregated form in PBS at 25 μM (Figure S15). The ability of PDI
3 to undergo internalization into both HeLa (human cervical
carcinoma) cells and T. brucei parasites was then assessed via
fluorescence microscopy (Figure 6 and Figure S16). After incu-
bating HeLa cells with 3 (5 μM) for 30 minutes, limited uptake
was observed (Figure S16A), however greater uptake was
Figure 5. (A) NMR titration of the telo22-Na+ G-quadruplex with DMSO as control ligand. (B–C) NMR titrations of (B) 1 and (C) 11 with the telo22-Na+ G-
quadruplex. Telo22-Na+ concentration was 185 μM in all cases, with 0 (black trace), 0.25, 0.50, 1, and 2 equivalents of ligand added (red traces). Orange
residues in the schematics denote interactions between the ligand and quadruplex. Solutions of DNA were prepared in 25 mM sodium phosphate buffer,
pH 7.0 containing 70 mM sodium chloride and 10% D2O. For full details, see Supporting Information.
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detected after 120 minutes (Figure S16B). The lack of colocal-
ized fluorescence with DAPI staining suggested limited pres-
ence of compound 3 in the nucleus, although it can be
observed in the rest of the cell. A similar scenario occurred for 3
when assayed in T. brucei. Uptake of 3 was observed after just
30 minutes incubation (Figure 6A), and remained after 120
Table 2. Cellular cytotoxicity and antiparasitic activity after 72 h incubation with 1 and 3–11 as well as Doxorubicin (MRC5/HeLa positive control), Suramin
(T. brucei positive control) and Miltefosine (L. major positive control). Reported as absolute EC50 values measured in μM using alamarBlue™ fluorescence (for
MRC5, HeLa and T. brucei) or MTT absorbance (for L. major) to assess cellular metabolism, with error represented as σ. SI = selectivity index. The best results
are highlighted in bold. Some data for 1 and Doxorubicin have been previously reported.[9]




Doxorubicin – 0.40�0.05 – –
Suramin – – 0.044�0.006 – –
Miltefosine – – 5.8�0.01 – –
1 3.9�0.5 0.5�0.05 0.61�0.3 0.47�0.07 9.5 6.4 8.3
3 2.1�0.6 53�6.2 0.027�0.01 >100 0.04 78 –
4 >100 >100 57�10 >100 – – –
5 >100 >100 67�18 >100 – – –
6 >100 >100 36�2 >100 – – –
7 >100 >100 70�13 >100 – – –
8 >100 >100 52�7 >100 – – –
9 88�10 29�3.5 33�24 >100 3.0 2.7 –
10 >100 >100 55�3 >100 – – –
11 59�37 14�1 2.8�2 18�1 4.2 21 3.2
Figure 6. Fluorescence microscopy images of T. brucei parasites after incubation with 3 (5 μM) for (A) 30 min or (B) 120 min respectively. Control parasites are
displayed in (C). Nuclear staining was performed using DAPI (blue fluorescence). Excitation was performed with the 350–450 and 492–518 filters for DAPI and
3, respectively. A triple filter (437–474, 508–550 and 595–670 nm) was used to detect the fluorescence emission of both DAPI and 3. Scale bar=5 μm.
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minutes (Figure 6B). DAPI staining of the nucleus and kineto-
plast also revealed no overlap with the fluorescence emission of
3. In both cases, the lack of fluorescence emission from 3 in the
nucleus or kinetoplast can be expected given that 3 exhibits
significant fluorescence quenching in the presence of small
quantities of DNA. In any case, further experiments would be
needed to rule out the possibility that 3 is unable to localize
into the nucleus and the kinetoplast.
Conclusion
In conclusion, we have developed a practical strategy for the
preparation of a diverse array of amphiphilic compounds using
simple yet versatile imide coupling chemistry, examining their
potential use as G4 ligands and as therapeutic agents. A library
of nine compounds with different core motifs were produced in
one step, from cheap, commercially available starting materials.
We have examined the role of the core motif in facilitating G4
binding, highlighting the importance of core rigidity such as in
the case of compounds 1 and 3. Most compounds with a
flexible or non-fused core did not induce G4 stabilization.
However, it is interesting to note that compound 11, containing
a flexible core and four positively charged groups arranged in
an octopus-like pose, is capable of G4 binding thus opening a
potential alternative strategy for developing G4 binders. In
total, four compounds showed binding to G4 DNA using FRET
and their interactions with a variety of G4 and duplex DNA
structures was assessed via CD, UV-Vis, Fluorescence, and NMR
titrations. The results revealed that previous NDI 1 exhibits
appreciable binding to duplex DNA, though 1 also displayed
100-fold selectivity for the mixed parallel/hybrid telo23-K+ G4
over the antiparallel telo22-Na+ G4. Compound 1 also seems to
interact with the telo22-Na+ G4 through end-stacking, which
corroborates the 2 :1 binding stoichiometry previously deter-
mined. The analogous PDI, 3, exhibited significant binding to
G4 DNA, and superior selectivity for G4 DNA over duplex DNA,
with a 40-fold selectivity for the telo23-K+ G4 over the ds26-K+
duplex. The core-diversification yielded a new linear, flexible
core with four non-fused aromatic rings and a much greater
degree of conformational freedom, that marks a departure from
the fused polycyclic aromatic NDI core on which it was based.
Di-substitution of this core (compound 9) was insufficient to
induce DNA stabilization, however the tetra-substituted ana-
logue 11 exhibited selective stabilization of G4 DNA over
duplex DNA, and interacted with specific residues at the top
tetrad and on one of the groves of the telo22-Na+ G4. The
anticancer and antiparasitic activity of the library was also
examined, with PDI 3 displaying potent toxicity towards T.
brucei, and 78-fold selectivity over control MRC5 cells. The
potent antiparasitic activity of 3 correlated with strong stabiliza-
tion of G4 DNA, although other modes of action could be
operating. Compound 3 was internalized into both HeLa cells
and T. brucei, and can be imaged at therapeutically relevant
concentrations (5 μM) with uptake that is time dependent. No
evidence for nuclear or kinetoplast uptake of 3 was found,
which could be due to the fluorescence quenching of 3 in the
presence of DNA. We hope this approach to diversify the core
of future G4 ligands may inspire other library-based convenient
approaches to G4 interactive compounds that could help
identify potent and selective G4 ligands with promising
therapeutic activity.
Supporting Information
Experimental Details, including further FRET melting experi-
ments, CD experiments, UV-Vis experiments, fluorescence
experiments, NMR experiments, cytotoxicity studies and
fluorescence microscopy is available in the supporting informa-
tion.
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